Berberis Oxalis
- Manufacturer
- Uriel Pharmacy Inc.
- Effective date
- 2024-12-02
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 5
- Source
- full-release
- Hydrated at
- 2026-06-01 02:29:17
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
INDICATIONS & USAGE SECTION
Directions: FOR ORAL USE ONLY.
DOSAGE & ADMINISTRATION SECTION
Dissolve pellets under the tongue 3-4
times daily. Ages 12 and older: 10 pellets.
Ages 2-11: 5 pellets. Under age 2: Consult
a doctor.
OTC - ACTIVE INGREDIENT SECTION
Active Ingredients: Berberis (Barberry) 1X,Oxalis (Wood sorrel) 3X, Sabal serr. (Dwarf palm) 3X, Urtica urens (Small nettle) 3X, Viscum Abietis (Fir tree mistletoe) 4X, Mag. sulf. (Magnesium sulfate) 6X, Prostata (Bovine prostate gland) 8X,Ferrum picrinicum 8X,Granite (Primitive rock containing quartz, feldspar, mica) 10X
INACTIVE INGREDIENT SECTION
Inactive Ingredients: Organic sucrose, Lactose.
Prepared using rhythmical processes.
OTC - PURPOSE SECTION
Use: Temporary relief of headache.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
KEEP OUT OF REACH OF CHILDREN.
WARNINGS SECTION
Warnings: Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated. Contains sugar. Diabetics and persons intolerant of sucrose (sugar): Consult a doctor before use. Do not use if allergic to any ingredient. Contains traces of lactose. Consult a doctor before use for serious conditions or if conditions worsen or persist. If pregnant or nursing, consult a doctor before use. Do not use if safety seal is broken or missing.
OTC - QUESTIONS SECTION
Questions? Call 866.642.2858
Uriel, East Troy, WI 53120
shopuriel.com
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
DailyMed Product Concepts#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 48951-2117-2 | Berberis Oxalis | 1350 in 1 BOTTLE, GLASS | PELLET | 1350 | 5 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 48951-2117 | BERBERIS OXALIS PELLET [URIEL PHARMACY INC.] | 5 | 1 package rows | 20241206_a65047b9-0207-4aa2-9a73-d4463687bdec.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| BERBERIS VULGARIS ROOT BARK | ACTIVE INGREDIENT | 1TH8Q20J0U | 1 | |
| BOS TAURUS PROSTATE GLAND | ACTIVE INGREDIENT | 1P66FXU2MW | 1 | |
| MAGNESIUM SULFATE | ACTIVE INGREDIENT | DE08037SAB | 1 | |
| OXALIS MONTANA LEAF | ACTIVE INGREDIENT | U1W3U02EW0 | 1 | |
| PENOXSULAM | ACTIVE INGREDIENT | 784ELC1SCZ | 1 | |
| SAW PALMETTO | ACTIVE INGREDIENT | J7WWH9M8QS | 1 | |
| URTICA URENS | ACTIVE INGREDIENT | IHN2NQ5OF9 | 1 | |
| VISCUM ALBUM FRUITING TOP | ACTIVE INGREDIENT | BK9092J5MP | 1 | |
| BERBERIS VULGARIS ROOT BARK | ACTIVE MOIETY | 1TH8Q20J0U | 1 | |
| BOS TAURUS PROSTATE GLAND | ACTIVE MOIETY | 1P66FXU2MW | 1 | |
| MAGNESIUM CATION | ACTIVE MOIETY | T6V3LHY838 | 1 | |
| OXALIS MONTANA LEAF | ACTIVE MOIETY | U1W3U02EW0 | 1 | |
| PENOXSULAM | ACTIVE MOIETY | 784ELC1SCZ | 1 | |
| SAW PALMETTO | ACTIVE MOIETY | J7WWH9M8QS | 1 | |
| URTICA URENS | ACTIVE MOIETY | IHN2NQ5OF9 | 1 | |
| VISCUM ALBUM FRUITING TOP | ACTIVE MOIETY | BK9092J5MP | 1 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 1 |
Products#
Every source-derived product name is available through these pages.
- Berberis Oxalis
- LACTOSE
- FERROUS PICRATE
- SUCROSE
- BERBERIS VULGARIS ROOT BARK
- OXALIS STRICTA WHOLE
- SAW PALMETTO
- URTICA URENS
- VISCUM ALBUM FRUITING TOP
- MAGNESIUM SULFATE, UNSPECIFIED
- MAGNESIUM CATION
- BOS TAURUS PROSTATE GLAND
- PENOXSULAM
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 48951-2117 | 48951-2117-2 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LACTOSE | J2B2A4N98G | IACT |
| FERROUS PICRATE | 4WC457HQ10 | ACTIB |
| SUCROSE | C151H8M554 | IACT |
| BERBERIS VULGARIS ROOT BARK | 1TH8Q20J0U | ACTIB |
| OXALIS STRICTA WHOLE | 3STW243384 | ACTIB |
| SAW PALMETTO | J7WWH9M8QS | ACTIB |
| URTICA URENS | IHN2NQ5OF9 | ACTIB |
| VISCUM ALBUM FRUITING TOP | BK9092J5MP | ACTIB |
| MAGNESIUM SULFATE, UNSPECIFIED | DE08037SAB | ACTIB |
| BOS TAURUS PROSTATE GLAND | 1P66FXU2MW | ACTIB |
| PENOXSULAM | 784ELC1SCZ | ACTIB |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 900 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / SUBCUTANEOUS | 47.75 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / RECTAL | 35.42 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 284e5bd7-a49d-06f7-e063-6394a90ab1ba | a65047b9-0207-4aa2-9a73-d4463687bdec | 2024-12-02 | Warnings | 284e5bd7-a49d-06f7-e063-6394a90ab1ba a65047b9-0207-4aa2-9a73-d4463687bdec |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
